NEOADJUVANT TRIAL DESIGNS
PERJETA, in combination with Herceptin® (trastuzumab) and chemotherapy, has been studied in multiple clinical trials for the neoadjuvant treatment of patients with HER2‑positive breast cancer.1
Learn more about the trial designs, endpoints, and baseline patient characteristics.